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High sensitivity detection of 
extracellular vesicles immune-
captured from urine by 
conventional flow cytometry
Carmen Campos-silva1, Henar suárez2, Ricardo Jara-Acevedo3, estefanía Linares-espinós4, 
Luis Martinez-piñeiro4, María Yáñez-Mó2 & Mar Valés-Gómez  1
extracellular vesicles (eVs) provide an invaluable tool to analyse physiological processes because they 
transport, in biological fluids, biomolecules secreted from diverse tissues of an individual. EV biomarker 
detection requires highly sensitive techniques able to identify individual molecules. However, the 
lack of widespread, affordable methodologies for high-throughput EV analyses means that studies on 
biomarkers have not been done in large patient cohorts. To develop tools for EV analysis in biological 
samples, we evaluated here the critical parameters to optimise an assay based on immunocapture of 
EVs followed by flow cytometry. We describe a straightforward method for EV detection using general 
EV markers like the tetraspanins CD9, CD63 and CD81, that allowed highly sensitive detection of 
urinary EVs without prior enrichment. In proof-of-concept experiments, an epithelial marker enriched 
in carcinoma cells, EpCAM, was identified in EVs from cell lines and directly in urine samples. However, 
whereas EVs isolated from 5–10 ml of urine were required for western blot detection of EpCAM, only 
500 μl of urine were sufficient to visualise EpCAM expression by flow cytometry. This method has 
the potential to allow any laboratory with access to conventional flow cytometry to identify surface 
markers on EVs, even non-abundant proteins, using minimally processed biological samples.
Most cell types release extracellular vesicles (EVs) during physiological processes. There exist different types 
of EVs, among which the term exosomes refers to nanovesicles (30–200 nm) released after fusion with the 
plasma membrane of intraluminal vesicles enclosed in endocytic compartments known as multivesicular bodies 
(MVB)1,2. Other types of EVs include microvesicles, which are usually larger than exosomes (200 nm-1 µm) and 
do not originate from the endocytic pathway, instead they bud from the plasma membrane3. There are several 
databases including information on the content of EVs: Exocarta4, EVPedia5, Vesiclepedia6, however, recent data 
have revealed that there is a great degree of heterogeneity among EVs and they exhibit different markers depend-
ing on the mechanism of release and the cellular origin7. Nanovesicles can be found in the extracellular milieu, 
like tissue culture supernatant, but also in biological fluids, like plasma and urine, and they carry many types 
of biomolecules, including proteins, lipids, mRNA, miRNA and DNA8. Therefore, EVs can mediate intercellu-
lar communication and macromolecules transfer and they also provide information about patho-physiological 
processes happening in an individual. Because EVs can be found in blood and urine, they have attracted much 
interest as potential biomarker targets and they are included in the recently coined term, liquid biopsy. This 
expression was initially used to refer to the analysis of the tumour burden by examining circulating tumour cells 
(CTCs) or DNA (ctDNA)9. Nowadays much research effort is being invested to understand the biological roles 
of circulating EVs, to identify their origin (distinguishing those from healthy cells from those associated with 
pathology) and to unveil their use as biomarkers. Progress in these research areas depends on the ability to sys-
tematically characterize EVs using standard, quantitative methods that allow comparison of results obtained in 
different laboratories and hospitals. The ideal new diagnostic tool should use small sample volumes of blood or 
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any other biological fluid for monitoring of the disease, allowing the generation of results from many samples in a 
laboratory user- friendly setting. Several methods are currently used for EV enrichment before further characteri-
zation; for example, serial ultracentrifugation steps10, precipitation11, density gradient separation or size exclusion 
chromatography12–14. Each of these techniques has advantages and disadvantages in terms of purity or enrich-
ment of EVs and the decision to utilize one or the other depends on the downstream use envisaged for the sample 
recovered and the importance of the impurities or co-isolated material found in each case. Size and concentration 
are currently measured by physical methods, such as nanoparticle tracking analysis (NTA) or conventional pro-
tein concentration tests, while their protein or nucleic acid content can be analysed by conventional laboratory 
methods like Western Blot and PCR. However, most of these methods for enrichment and characterization are 
expensive and time consuming and essentially make impossible the screening of a large number of samples.
An important step in EV characterization relies on determining the molecular composition of vesicles and 
identifying markers of disease. Choosing universal exosome markers is challenging because of cell-to-cell vari-
ability and differential expression in different types of EVs. Moreover, there is little information about how bio-
logical processes, such as tumor transformation, affect the relative amount of protein markers recruited into EVs. 
However, recent data comparing the composition of EVs isolated after different centrifugation speeds (2000 × g, 
10,000 × g and 100,000 × g pellets) make it clear that CD63, CD9, CD81 or combinations of these molecules are 
enriched in EVs derived from different cell lines, although these preparations may also contain non-EV material 
co-purified with EVs7. Depending on the cell origin, the 100,000 × g pellet can contain small (30–50 nm) or 
larger (50–200 nm) vesicles2. Thus, immunocapture, using tetraspanins CD63, CD9 and CD81, or other mol-
ecules generally found in EVs, such as TSG101, Alix, etc15, can provide a tool to selectively enrich EVs from a 
complex preparation. Although there are some studies reporting successful immunocapture of EVs, the assay 
conditions need to be individually optimised depending on the readout technique that will be used afterwards 
and implementation of the methodology varies significantly among different laboratories. For example, we and 
others have reported EV detection using enzyme-linked immunosorbent assays (ELISA)16–18 or lateral flow 
immunoassays (LFIA)17,18 demonstrating that each one of these techniques has different critical steps affecting 
sensitivity. Novel techniques using immunocapture-based microfluidics19 or time-resolved fluorescence immu-
noassay (TR-FIA)20 can also provide a very good research tool for EV screenings, however the use of specialized 
equipment and appropriately trained operators is required. Immune-capture followed by flow cytometry detec-
tion, in general requires immobilization of the nano-sized EVs on microbeads; although a range of differently 
sized vesicles are released by cells, average exosomes have a diameter of around 100 nm and the laser beam of 
the flow cytometer does not resolve light scattered by particles smaller than 300 nm (these particles fall together 
with cell debris, protein or antibody aggregates in FSC plots), unless a special flow cytometer with a modified 
laser is used21–24. For conventional flow cytometry, microbeads with different composition (latex, polystyrene, 
etc), different sizes (4–9 microns in diameter) and different functionalization (antibodies, streptavidin, alde-
hyde sulphate) have been already employed25–28. All these studies demonstrate that, once the size limitation is 
overcome by coupling to microspheres, EVs can be visualised by flow cytometry allowing specific analysis of 
proteins on their surface. However, in all these settings either large amounts of starting material or previously 
enriched EVs were required. With the aim of establishing a standard reproducible methodology for detection of 
EVs by flow cytometry and to improve available methods for EV characterization, here, we defined the critical 
parameters necessary to increase EV detection capacity by flow cytometry, after immune-capture on magnetic 
fluorescent beads coated with tetraspanin-specific antibodies. We have defined the conditions to achieve very 
high sensitivity detection of EVs, so that biological samples can be analysed with minimal sample processing. 
In fact, we could detect CD9-containing vesicles directly in as little as 500 µl of urine from healthy donors after 
capture on anti-CD63-coated beads. Furthermore, extracellular vesicles captured on anti-EpCAM coated beads 
were detected directly in urine.
Results
Characterization of EVs from the prostate cell line PC3. To improve the methodology for optimal EV 
immune capture on magnetic microbeads, followed by flow cytometry detection, we focused on the study of vesi-
cles from a broadly used cell line from prostate cancer, PC3. Initial experiments for optimization of the procedure 
were carried out using PC3-derived EVs, either commercially available or purified in our laboratory by sequential 
ultracentrifugation and preserved by lyophilization. Firstly, EVs were characterised by NTA and Western Blot 
(Fig. 1A,B; Supplementary Fig. 1). Reconstituted EVs showed by NTA a mean size of 188.4 +/− 1.9 nm (Standard 
error; SD: 86 nm), a concentration of 4.59∙108 +/− 1.49∙107 particles/ml and contained the common markers of 
EVs; the tetraspanins CD63, CD81 and CD9. Moreover, the EV fraction from PC3 was enriched in CD9, com-
pared to the cell lysates and did not contain calreticulin, an ER marker, present in cell lysates (Supplementary 
Fig. 1). In addition, PC3-derived EVs were positive for EpCAM, an epithelial cell marker.
Theoretical considerations for immune capture of EVs on microbeads. To establish the conditions 
for a high sensitivity method of EV immune-capture, we first considered which parameters are critical to get the 
best signal-to-noise ratio performance in a flow cytometer. Because there is a linear relationship between the 
intensity of fluorescence detected in a flow cytometer and the amount of a given fluorochrome per cell (in our 
case, per bead)29, the fluorescence signal will be maximum if the number of EVs captured per bead tends towards 
saturation. Thus, for optimal signal detection two parameters need to be carefully established: (1) the total num-
ber of beads acquired per experiment, and (2) the number of EVs that contain the epitope used for capture. 
Moreover, since our goal is to analyse biological samples, the optimization has to take into account that EVs could 
be diluted in a large volume, for example, in urine and, in this case, the dilution factor could be important. In 
other biological samples, such as plasma or serum, EVs derived from unhealthy cells or tumours could be mixed 
with large amounts of EVs released by normal tissues (as well as all the other usual components of human serum). 
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Thus, non-abundant markers for tumour or stress would be needed to capture the EVs of interest. So, given that 
the relevant EVs can be in limiting amounts in biological fluids, the assay should be optimised using the minimal 
number of beads that allows reproducible statistical analysis of the events acquired by the flow cytometer. For a 
better understanding of the system, we estimated the maximum binding capacity per bead, assuming that the 
whole surface of the bead would be covered with antibody and that a monolayer of EVs would be coupled to the 
bead. The maximum number of EVs captured per bead was calculated superimposing on the surface of a sphere 
(Sbead) the number (N) of EV circle surfaces (Cexo, taking as average diameter, 150 nm) which could fit in that area; 
N was calculated as the ratio N = Sbead/Cexo (Fig. 2). This average diameter was taken because, in our previous 
experiments18, the average size of exosomes purified by ultracentrifugation was nearly 200 nm by NTA, but EM 
pictures revealed particles near or below 100 nm, and this was also true for the EVs used here. According to this 
calculation, a 6 μm bead would bind a maximum of 6420 EVs. If the cytometer acquired 3000–6000 beads per 
test, a sample with 1.93–3.85 × 107 EVs would saturate the beads. These calculations assume that all the EVs in 
the mix would be able to get in contact with the beads, however, beads and EVs in solution have different phys-
ical behaviour due to their difference in size and density, so that the beads can precipitate to the bottom of the 
tube while EVs would remain in suspension longer time. On the other hand, the number of antibody molecules 
reported to bind T lymphocytes under saturating conditions, for bright epitopes such as CD4, has been reported 
to be around 2–4 ∙ 104 30,31. Thus, the fluorescence intensity should be detectable even in the case that only half of 
the binding surface of the bead was covered by EVs, that is, around 3200 EVs, if each EV was recognised by 6–12 
molecules of detection antibody.
Specificity of immunocapture using anti-tetraspanin antibodies. The assay was designed using 6 
μm antibody-coated fluorescent magnetic microbeads as depicted in Fig. 2B. Taking into account previous cal-
culations, the starting point was established as 2 µg of EVs from PC3 (109 EVs), which should provide a good 
excess for capture with 3000–6000 beads, even in the case that not all the EVs in the sample expressed the epitope 
used for immunocapture. The gating strategy excluded bead aggregates and debris by FSC/SSC and selected the 
acquisition number in the region of APC-positive microbeads (Fig. 3A). To confirm the specificity of the recog-
nition, microbeads covered with irrelevant antibody (murine IgG1 control protein) were used to compare flow 
cytometry signals (Fig. 3B). Capture conditions were optimised trying different volumes, temperatures and times 
of incubation followed by detection with PE-conjugated anti CD81 antibody (Supplementary Fig. 2). A stronger 
signal was detected when EVs were incubated without agitation with 6000 antibody-coated beads for 18 h at RT. 
Antibody blocking experiments were also performed including a sample pre-incubation step with the same anti-
body used for immunocapture (either purified anti-CD63 or anti-CD9 antibodies) (Fig. 3C). 50 ng of antibody 
were sufficient to completely block binding of the EVs to the microspheres.
EV detection using CD63 antibody for capture. Limit of detection. CD63, CD9 and CD81 are gen-
eral markers of EVs, however, these tetraspanins can be present in different amounts on EV subpopulations. In 
Figure 1. Characterization of PC3-derived EVs. (A) Nanoparticle tracking analysis (NTA). Average size 
and concentration were obtained in a Nanosight equipment capturing 3 videos of 60 s per measurement, 
with a focus −15 to +15 and camera level 12. ɸ: diameter. (B) Western Blot. EVs were loaded on SDS-PAGE 
and immunoblotted for β-actin (Sigma) and antibodies against tetraspanins [anti-CD9 (MEM62), -CD63 
(MEM259) and -CD81 (MEM-38)]. Three gels were loaded: one gel, under non-reducing conditions with 
2.2·109 particles, for CD9 and CD81 detection, exposed for 2 min; a second non-reducing gel with 6.8 · 109 
particles, for CD63 detection, exposed for 1 h; and the third gel under reducing conditions, for actin detection, 
exposed for 40 s. The experiment shown is representative of 4.
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addition, different antibodies against different tetraspanins provide another source of variation depending on 
affinity of the interactions. Thus, we determined the optimal combination of tetraspanin capture and detection 
antibodies for flow cytometry visualization of PC3 EVs. Anti-CD9 antibody or anti-CD63 antibody coated mag-
netic microspheres were incubated for 18 h with PC3 EVs (or without EVs for negative control) and thereafter 
stained with either anti-CD63, anti-CD9 or anti-CD81 antibodies for detection. The number of EVs (4 × 109 
particles) used in each one of the assays was kept constant. The best efficiency (positive vs negative signal and 
highest absolute number) was observed using anti-CD63 antibody coated magnetic microspheres for capture 
(Fig. 4). To compare the relative staining obtained with the different antibody combinations, the fluorescence 
intensity was evaluated taking into account the peak distance between the positive sample and the background as 
well as the spread of the negative. Thus, the Relative Stain Index (SI) was calculated according to the formula, 
=
σ
–SI MFI positive MFI background
background2
. An alternative measurement of relative brightness is the signal-to-noise ratio, 
Relative Fluorescence Intensity (RFI), calculated as RFI = MFI positive
MFI background
 32,33. Results show that, although CD63 was 
in general a less abundant protein than CD9 or CD81 in PC3 EVs, as judged by the higher time of exposure 
required for CD63 in WB experiments, the CD63-specific mAb was suitable for capture yielding high SI and RFI 
when either CD9 or CD81 mAbs were used for detection. In contrast, CD63 was not as efficient when used as 
detection antibody. Using CD63 for capture, allowed to further amplify the signal using fluorescent streptavidin 
binding biotinylated antibodies against the abundant tetraspanins CD9 and CD81. (Supplementary Fig. 3A).
Next, to determine the dynamic range and limit of detection of the assay, EV titration experiments were per-
formed using CD63 for capture and CD9 for detection (Fig. 5A). Different amounts of EVs were also tried on 
IgG1-coupled beads with minimal increase in fluorescence intensities (For example, Supplementary Fig. 3B). The 
sensitivity of the assay was very high, with a positive signal detected when as little as 30 ng (1.37∙107 particles) of 
EVs were incubated with the microspheres (Fig. 5B), while for detection of CD63 by Western Blotting 6.8 · 109 
particles (14.85 µg) were required. Flow cytometry detection data followed a linear distribution between 30 ng and 
8 μg (R² > 0.98, for both RFI and SI), corresponding to 1.37∙107–3.67∙109 particles. The minimum amount of EVs 
necessary for a reliable detection can be defined by calculating the SI allowing complete separation of the 2 peaks, 
that is, when SI > 1, meaning that the two peaks would be completely resolved and separated by 2 times the stand-
ard deviation of the normal distribution. We could define the minimal value for a reliable limit of EV detection by 
flow cytometry as 142 ng of EV (7∙107 particles), by interpolating in the polynomic curve when SI = 1.
To confirm that EVs from different sources could be detected using flow cytometry, EVs from different cell 
lines were enriched by sequential centrifugation from tissue culture supernatant. The different cell lines displayed 
varying amounts of CD63 and CD9 as detected by WB, however, immune-capture followed by flow cytometry 
detection was possible for all of them with higher sensitivity than WB (Supplementary Fig. 4). EVs from MCF-7, 
RT-112, SK-Mel-147, Ma-Mel-55, SK-Mel-28 cell lines could be detected (also from HEK293 and SUM149 not 
shown). SI and RFI co-related with the intensity of the protein detected by WB in the same sample, being lower 
for SK-Mel-147 which displayed fainter bands for CD63 and CD9.
EV proteins can be detected in small amounts of minimally processed urine. Since the experi-
ments above revealed a very high sensitivity for detection of EVs after pre-enriching by ultracentrifugation, we 
Figure 2. (A) Theoretical calculation of the number of EVs immobilised per bead. The graph represents at real 
scale a 6 μm-diameter bead and an EV of 150 nm of diameter (ɸ). The external surface of a bead (Sbead) could 
capture a maximum of N times the circle area (Cexo) of 150 nm EVs. N is calculated by dividing Sbead/Cexo. (B) 
Schematic representation, not to scale, of the bead binding assay. 6 μm-diameter fluorescent magnetic beads 
were coated with capture antibody and used for immune-capture of the EVs. A second antibody directed against 
the same or a different molecule, either biotinylated or directly conjugated with PE, was used for detection. In 
the case of biotinylated antibodies, PE-conjugated streptavidin was subsequently used. Samples were analysed 
by conventional flow cytometry.
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hypothesised that it would be possible to implement the assay in body fluids without previous enrichment of EVs. 
The basic assay of immune-capture on CD63 beads and detection using biotinylated-anti-CD9 was used first to 
detect EVs enriched by ultracentrifugation from healthy donor urine, with very high SI and RFI, 27.8 and 31.53 
respectively (Fig. 6A). Next, only 500 µl of urine from healthy donors was analysed by flow cytometry. Although 
for most experiments, urine was pre-treated with mild reduction to eliminate Tamm-Horsfall protein (THP) 
aggregates, we could visualise EVs in urine samples in which only cell debris were eliminated by centrifugation at 
400 × g (Supplementary Fig. 5A). EVs from 500 µl of urine were captured with anti-CD63 antibody and detected 
by flow cytometry using biotinylated-CD9 antibody. As negative control, IgG1-coated beads were incubated with 
500 µl of urine from the same sample (Fig. 6B). The combination of anti-CD9 for both capture and detection also 
allowed visualization of the EVs by flow cytometry (Supplementary Fig. 5B).
The ability to detect EVs in a small volume of urine together with the results showing that the capture anti-
body does not need to recognise an abundant protein for efficient immobilization of EVs, implies that all kind 
of different markers could be studied using this methodology. One of the most promising areas in the field of 
EVs consists in their use as tumour biomarkers. To formally prove this hypothesis, we decided to use EpCAM, a 
common marker found in epithelial carcinomas, in combination with tetraspanins. EpCAM is expressed in nor-
mal epithelial cells but is generally upregulated in carcinoma cells compared with healthy epithelia34–36 and the 
recruitment of this protein to EVs has been described in cell lines and patient biological fluids37,38. PC3 cells are 
positive for EpCAM36 and the protein was also detectable in cells and PC3-derived EVs by WB (Supplementary 
Fig. 1). Thus, several antibody combinations were tried next for detection by flow cytometry of EpCAM in EVs 
from prostate cancer cells. Firstly, PC3-derived EVs captured on anti-CD63 coated beads were analysed by flow 
cytometry using biotinylated anti-EpCAM antibody for detection and, then, using magnetic beads coated with 
anti-EpCAM antibody, followed by detection with anti-CD9 antibody (Fig. 7A,B). Both antibody combinations 
allowed detection of the EpCAM positive EVs with RFI values above 10. The specificity of EpCAM-coated beads 
was tested in blocking experiments using PC3-derived EVs (Fig. 7C). Also, specific binding was demonstrated by 
Figure 3. Specificity of EV immunocapture on antibody-coated microbeads. (A) Gating strategy. EVs 
immobilised on 6 μm APC-beads were stained using biotinylated antibody followed by PE-conjugated 
streptavidin and analysed by flow cytometry. A gate containing only single beads was created in the Forward 
Scatter (FSC)/Side Scatter (SSC) plot. A second gate, within single beads, confirmed the APC fluorescence of 
microbeads. 1500–2000 events from this combined gating were acquired and analysed for PE labelling. (B) 
Negative control, IgG1. 109 particles of PC3-derived EVs were captured onto either anti-CD63 (Clone TEA3/18) 
or IgG1-coated beads followed by detection with biotinylated antibody directed against CD9. A sample with no 
EVs is also shown for comparison. (C) Antibody blocking. 109 particles of PC3-derived EVs were pre-incubated 
with increasing amounts of the indicated soluble blocking antibody [anti-CD63 (Clone TEA3/18), anti-CD9 
(Clone VJ1/20)] before being incubated for capture on CD63- (left) or CD9- (right) coated beads. Experiments 
are representative of 3 independent repetitions.
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comparing the signals obtained with EVs from the EpCAM-negative cells, SK-Mel-28 (Supplementary Fig. 4), on 
beads coated either with EpCAM, CD63 or IgG1 (Fig. 7D).
The expression of EpCAM was analysed directly in urinary EVs from 9 donors that attended the urology clinic 
with prostate swelling or suspected cancer36,39. Urine samples were used for parallel determinations of EpCAM on 
EVs: (1) EVs enriched by ultracentrifugation from 8 ml of starting urine were analysed by Western Blot (Fig. 7E); 
(2) 500 μl of urine were analysed by capture on anti-EpCAM coated beads followed by detection using biotiny-
lated anti-CD9 by flow cytometry (Fig. 7F). Expression of EpCAM was detected by flow cytometry in 7 of the 9 
samples available, while only in 6 samples this marker was detectable by WB. Thus, in these experiments, flow 
cytometry allowed detection of EpCAM on EVs with higher sensitivity than WB, confirming that this method 
can be used to phenotype EVs even in small amounts of biological samples and thus allow larger screening stud-
ies. Our results provide a proof-of-concept for direct detection of tumour markers in EVs from urine samples by 
immune capture followed by flow cytometry.
Discussion
The field of EVs has benefited in the last years from intense research which has very rapidly yielded information 
on their molecular content in health and disease. As a result, much interest has been attracted to the possible use 
of EV-expressed molecules as biomarkers in a number of pathologies. Although EVs can be very accessible in 
biological fluids, their low concentration in particular EV populations and/or specific EV molecules together with 
the heterogeneity in their origin, and thus in molecular composition, make it difficult to screen a high number of 
samples for biomarker analysis and validation. Thus, it is important to develop methodologies that would allow 
such high throughput studies using, when possible, generally available techniques. Here, we describe a highly 
Figure 4. Optimization of tetraspanin antibody combination. 4∙109 particles of PC3-derived EVs were captured 
onto either anti-CD9 (Clone VJ1/20) or anti-CD63 (Clone TEA3/18) coated beads followed by detection with 
PE-conjugated antibodies directed against CD9, CD81 or CD63. The sensitivity of each antibody combination is 
compared using the Stain Index (SI) =
σ
–SI MFI positive MFI background
background2
, where σ is the standard deviation and MFI 
Mean Fluorescence Intensity; and the Relative fluorescence Index (RFI), =RFI MFI positive
MFI background
, indicated on the 
upper right corner of each panel. A representative experiment out of 3 is shown.
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sensitive reproducible method for immune capture of EVs followed by conventional flow cytometry detection 
that allows characterization of small amounts of vesicles, even directly from as little as 500 μl of minimally pro-
cessed urine. Our results demonstrate that using antibody-coated magnetic microbeads it is possible to detect 
non-abundant proteins on EVs in a wide concentration range, with a limit of detection below that of Western 
Blotting. Further, the use of conventional flow cytometry provides the advantage of allowing easy implementation 
in nearly any research institute or hospital laboratory.
Several immune-capture methods are currently under study for the characterization of EV composition. In 
fact, several companies commercialize kits to perform such types of assays. The use of antibodies to bind a specific 
marker allows, in principle, to distinguish vesicles originated from different cells, compartments or organs and 
to selectively study different vesicle subpopulations, as well as to avoid the analysis of contaminants accumulated 
during ultracentrifugation. However, the experimental strategies using immunocapture vary markedly, and the 
sensitivity of different types of assays can be critically affected at different steps. For this reason, we considered 
here the theoretical critical parameters necessary for a reliable detection by flow cytometry and carefully com-
pared the conditions to perform the test. Although changes in the conditions of temperature and incubation time 
could clearly affect binding of EVs to the microbeads, one of the main factors necessary to improve the assay 
sensitivity relies on the relative size and number of microbeads and vesicles in the analysis.
Figure 5. Dynamic range and limit of detection. EVs were captured on anti-CD63-coated beads followed by 
detection with biotinylated anti-CD9 antibody (Clone VJ1/20). (A) Flow cytometry analysis profiles. Increasing 
amounts (30 ng to 10 μg; 1.37∙107–4.59∙109 particles) of PC3-derived EVs were captured on 6 μm beads and 
detected by flow cytometry. The total volume of the assay was 100 μl. The graph represents the overlay of the 
curves obtained. The legend indicates the amount of EVs and the RFI for each curve. (B) Regression analysis. 
RFI (right) and SI values (left) were plotted as a scatter graph and fitted to a polynomic curve (upper panel). 
Linearity can be observed between 0.2–8 µg of PC3-derived EVs with a r2 > 0.98 (lower panels). The minimal 
amount of EVs detected (RFI > 1), corresponds to 30 ng yielding a RFI of 1.08. A representative experiment out 
of 3 is shown.
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The assay reported here allows detection of EV populations (as Relative Stain Index, SI, and Relative 
Fluorescence Index, RFI) both when using tetraspanins, as general EV markers, or by using a specific marker of 
epithelial cells, EpCAM. Moreover, for effective capture of EVs, it was not necessary to use the more abundant 
antigens detected by WB. Because multiple proteins can be exposed on the vesicle, binding is favored by avidity 
and, thus, if the antibody’s affinity and specificity are good, the abundance of the antigen is not a limiting factor 
for capture. This is demonstrated by the effective capacity of the anti-CD63 antibody used here to capture EVs, 
even if this protein was less abundant than other tetraspanins in the sample.
The method for EVs immunocapture and flow cytometry analysis described here has higher sensitivity than 
WB for individual proteins and allows the detection of several combinations of epitopes. While 6.8·109 particles 
were needed for WB detection of CD63, 1.37·107 particles were detected by flow cytometry, increasing the pos-
sibility of visualising almost any marker. Moreover, the method provides the advantage of making possible the 
study of different epitopes on the captured vesicles allowing confirmation of the presence of multiple markers in a 
population of EVs. This could be further developed for the study of more protein markers, using combinations of 
several fluorescent antibodies and provides the possibility of easily adapting to this method a multiplex analysis, 
including microbeads coated with different antibodies, taking advantage of the fluorescence feature of the beads.
The high sensitivity of the assay allowed detection of protein markers directly in urine. This direct detection 
opens the way to compare data among different laboratories with high reproducibility, since the heterogeneity 
introduced by EV isolation techniques could be eliminated. We demonstrated the possibility of detecting general 
markers of EVs in urine from healthy donors and provided the proof-of-concept for the detection of cancer mark-
ers directly in urine of prostate cancer patients. The methodology reported here can be easily adapted to examine 
larger cohorts of patients and different tumour markers to establish the link between EV-expressed proteins 
and disease progression. This method complements the one recently reported by Sharma et al.28, in which EVs 
isolated from melanoma patients plasma were detected by flow cytometry using a specific marker for melanoma. 
Further, the method reported here shows increased sensitivity with RFI values above 30 for purified EVs and 
Figure 6. Detection of EVs from healthy donors urine. (A) Purified EVs from urine. 68 µg (6.8∙1010 particles) of 
EVs from healthy donors (Hansa Biomed) were analysed by Western Blot for detection of CD63 (1 h exposure), 
CD81 (10 min exposure), CD9 (10 s exposure) and β-actin (10 min exposure) (left). 10 µg (109 particles) were 
captured onto anti-CD63-coated beads followed by detection with biotinylated anti-CD9 antibody by flow 
cytometry (right). (B) EVs contained in 500 µl of urine analysed by flow cytometry. 500 µl of healthy donor 
urine was pre-treated by mild reduction (see methods) and incubated with either anti-CD63- or IgG1-coated 
beads followed by detection with biotinylated anti-CD9 antibody by flow cytometry. Stain Index (SI) and the 
Relative fluoresce Index (RFI) are indicated inside each panel. A representative experiment out of 3 is shown.
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allowed detection without previous enrichment. Therefore, the use of flow cytometry for routine screening of 
biological samples can become a reality for patient classification and treatment follow-up. Further normalization 
studies should be needed for the screening of patient urine, including: 1/Normalization of dilute versus concen-
trated urine due to donor hydration. This can be addressed measuring creatinine which is constantly released 
under normal kidney filtration function; 2/Normalization of donor-to-donor variation, can be addressed using 
the IgG beads which can detect variations in autofluorescence or any contaminant causing non-specific binding; 
3/changes in the amount of EVs released by each donor due to their particular patho-physiological events. This 
Figure 7. Direct detection of EpCAM in urinary EVs. (A) EpCAM detection on PC3-derived EVs. 10–20 µg 
(4.59–9.18∙109 particles) of PC3-derived EVs were captured onto anti-CD63-coated beads followed by detection 
with biotinylated anti-EpCAM antibody by flow cytometry. (B) 5–10 µg (2.29–4.59∙109 particles) of PC3-
derived EVs were captured onto anti-EpCAM-coated beads followed by detection with biotinylated anti-CD9 
antibody by flow cytometry. (C) Specificity of anti-EpCAM-coated beads: antibody blocking. To confirm the 
specificity of anti-EpCAM-coated beads, PC3-derived EVs were pre-incubated with anti-EpCAM antibody, 
previously to their incubation with microbeads. (D) Specificity of anti-EpCAM-coated beads: negative control. 
1.78∙109 particles of SK-Mel-28-derived EVs (EpCAM-negative cell line) were captured onto either anti-CD63-
coated beads, anti-EpCAM- or IgG1-coated beads followed by detection with biotinylated anti-CD81 antibody 
by flow cytometry. (E) Detection of EpCAM by WB in EVs from 8 ml of urine. 8 ml of pre-treated urine from 
3 healthy donors (HD) and 6 patients (P1- P6) were used to purify EVs by ultra-centrifugation and they were 
analysed by WB. The number under the EpCAM panel corresponds to the Relative fluoresce Index (RFI) in 
the flow cytometry experiment. (F) Detection of EpCAM by flow cytometry in EVs from 500 µl of urine. 500 µl 
of pre-treated urine were incubated with either IgG1 or anti- EpCAM-coated beads followed by detection 
with biotinylated anti-CD9 antibody and flow cytometry analysis. Three flow cytometry experiments were 
performed using the same patient samples and the results from a representative experiment are shown.
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requires clinical research on markers that are more or less abundant, or completely absent, in the context of dif-
ferent diseases.
In conclusion, we have maximized fluorescence detection on immunocaptured EVs to develop a robust and 
reproducible assay allowing protein phenotyping with high sensitivity. We also provide the proof-of-concept for 
the detection of EV markers, such as tetraspanins and EpCAM directly in urine.
Materials and Methods
Cells lines and reagents. Cell lines from prostate (PC3), renal carcinoma (HEK293) and melanoma 
(Ma-Mel-5540, SKMel147, SKMel28) were grown in RPMI 1640 with 10% fetal bovine serum (FBS), L-Glutamine 
1 mM, Penicillin and Streptomycin 100 μg/ml, Sodium Pyruvate 1 mM, non-essential aminoacids 0.1 mM and 
HEPES 10 mM, at 37 °C. Bladder cancer cells (RT-112) were cultured in DMEM with the same supplements. The 
human breast carcinoma cell line SUM159 was cultured in DMEM/F-12 (Life Technologies, Invitrogen, Carlsbad, 
CA), supplemented with 5% FBS, nonessential amino acids, 5 μg/ml insulin and 1 μg/ml hydrocortisone. The 
breast cancer cell line MCF-7 was cultured in DMEM, 10% FBS, 1% penicillin/streptomycin, Sodium Pyruvate 
1 mM and 10 μg/ml insulin.
Antibody-coated magnetic beads were obtained from the Exostep™ kit (Immunostep, Ref: ExoS-25-U) or 
prepared by incubating magnetic fluorescent beads either from Luminex (MagPlex Microsphere, Ref: MC10012) 
or Bangs (QuantumPlex M SP Carboxil, Ref: 251A) with purified anti-CD63 (Clone TEA3/18), purified anti-CD9 
(Clone VJ1/20) or anti-EpCAM (Clone VU-1D9) antibodies from Immunostep, S.L. Magnetic fluorescent beads 
were coated with high density carboxyl functional groups on the surface, these groups were used to covalently 
conjugate antibodies through their primary amines by two-step EDC/NHS protocol producing a stable amide 
bond.
Unless otherwise stated, all chemicals were purchased from Sigma-Aldrich.
EV extraction and isolation. For comparison of different cell lines, EVs were isolated from cell culture 
supernatants by sequential centrifugation as previously described41. Cells were cultured for 72 hours to 7 days in 
a medium containing 1% exosome-depleted FBS (prepared by centrifugation for 20 h at 100,000 × g). After the 
final centrifugation at 100,000 × g, EVs were resuspended in Hepes-buffered saline buffer (HBS: 10 mM HEPES 
pH 7.2, 150 mM NaCl). For some experiments, lyophilized exosome standards from PC3 cell culture supernatant 
were purchased from HansaBiomed or Immunostep, S.L. (Ref: ExoPC3). Lyophilized exosomes from human 
urine of healthy donors were purchased from HansaBiomed. Lyophilised EVs from PC3 cell culture supernatant 
were resuspended at 1 µg/µl.The protein amount, corresponding to the μg of EVs, has been calculated by BCA 
assay, which assesses the total protein content.
EV quantitation by nanoparticle tracking analysis. Concentration and size of EVs were determined by 
nanoparticle tracking analysis (NTA) in a Nanosight NS500 (Malvern Instruments Ltd, Malvern, UK) equipped 
with a 405 nm laser. The settings used were: Camera level:12, Focus between −15 and +15, Threshold: 10, 
Capture: 60 s., Number of Captures: 3, Temperature 25 °C. These experiments were carried out in the laboratory 
of Dr. H Peinado, at the Spanish National Centre for Oncological Research (CNIO).
Western Blot. Equal amounts of EVs (6.8 · 109 particles) were loaded in 10% SDS-PAGE gels, either under 
reducing or non-reducing conditions, as indicated in the experiments, and transferred to membranes with 
Trans-Blot® Turbo™ Transfer Packs (Biorad). Membranes were blocked using 5% non-fat dry milk in PBS contain-
ing 0.1% Tween 20 (PBS-T). Primary antibody was incubated for 1 h in PBS-T and, after washing, membranes were 
incubated with the appropriated secondary antibody. Proteins were visualized using the ECL system (Amersham 
Biosciences). Antibodies used were: monoclonal anti β-actin produced in mouse (Sigma) at 0.13 µg/ml; 
purified mouse monoclonal anti-CD9 (MEM62), -CD63 (MEM259) and -CD81 (MEM-38) antibodies (kind 
gifts from Vaclav Horejsi, Croatia); horseradish peroxidase-conjugated goat anti-mouse antibody (Dako). Rabbit 
polyclonal anti-calreticulin (Novus Biologicals) was used for WB at 4 µg/ml and biotinylated anti-EpCAM (clone 
VU-1D9) at 1 µg/ml.
EV flow cytometry. EVs were incubated with 6000 antibody-coated beads in 100 μl of PBS containing 1% 
casein for 18 h, in a 5 ml tube without agitation at room temperature (RT). After the binding step, beads were 
stained with either anti-CD63 (Clone TEA3/18), anti-CD81 (MEM-38) or anti-CD9 (Clone VJ1/20) antibodies 
(Immunostep, S.L.), either biotinylated or PE-conjugated. After antibody binding, beads were washed with fil-
tered PBS containing 1% BSA, and recovered using a Magnetic Rack (MagneSphere(R) Mag. Sep. Stand 12-hole, 
12 × 75 mm (Promega, Ref Z5343). When using biotinylated antibody, a step incubating with streptavidin-PE 
(Immunostep, S.L.) was added followed by bead washing with PBS-1% BSA. When analysing urine samples, 500 μl 
of urine supernatant (see below) were directly incubated with 3000 microbeads. Samples were analyzed using 
either Gallios or Cytomics FC 500 (Beckman Coulter) or FACSCalibur Flow Cytometers (Becton Dickinson) 
and data were analysed using Kaluza (Beckman Coulter) and FlowJo (Tree Star, Inc). Single beads were gated 
in Forward Scatter in the region corresponding to 6 µm (established using calibration beads (FlowCheck ProTM 
fluorospheres, Beckman Coulter), excluding bead doublets and non-bead events in FSC/SSC and selecting beads 
using the corresponding channel of fluorescence. The percentage of single beads was above 95%.
Urine samples. Urine from 3 healthy donors and 8 patients with enlarged prostate was collected at the 
Urology Service at University Hospital La Paz (Madrid). Of these donors, two were excluded from the analysis: 
one did not contain EVs by WB; the second had large amounts of macroscopic aggregates in the urine after a 
first centrifugation at 200 × g. All volunteers signed an informed consent form with the ethical approval of the 
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Institutional Review Board and local ethical committees (CEI La Paz Hospital HULP-PI 2978). The study con-
formed to the principles expressed in the Declaration of Helsinki.
10 ml of urine were centrifuged at 400 × g to remove cells and Tamm-Horsfall protein (THP) aggregates, this 
initial pellet was treated for 10 min with 28 µl of 100 mM DTT, and after centrifugation at 400 x g the supernatant 
was transferred to the previous 10 ml of urine supernatant (final concentration of DTT 0.28 mM).
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